CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired KWS BioTest Limited for $20.3 million in cash, a transaction completed in January 2018, structured as all cash.
KWS BioTest Limited operates in Discovery and Safety Assessment (DSA), is based in United Kingdom. KWS BioTest was a CRO specializing in in vitro and in vivo discovery testing services for immuno-oncology, inflammatory and infectious diseases.
The acquisition enhances our discovery expertise, with complementary offerings that provide our customers with additional tools in the active therapeutic research areas of oncology and immunology. The purchase price for KWS BioTest was $20.3 million in cash.
DSA segment, discovery services
The acquisition enhances our discovery expertise, with complementary offerings that provide our customers with additional tools in the active therapeutic research areas of oncology and immunology. The purchase price for KWS BioTest was $20.3 million in cash.Charles River FY2018 10-K, Business Acquisitions note
Advisory firms were not disclosed for this transaction.